Nativi-Nicolau, Jose N.
Karam, Chafic
Khella, Sami
Maurer, Mathew S.
Funding for this research was provided by:
Akcea Therapeutics
Article History
Accepted: 26 January 2021
First Online: 20 February 2021
Declarations
:
: Jose N. Nativi-Nicolau reports funding for clinical trials from Pfizer, Akcea Therapeutics, and Eidos; educational grants from Pfizer; and consulting fees from Pfizer, Eidos, Akcea Therapeutics, and Alnylam. Chafic Karam reports consulting/educational activities for Akcea Therapeutics, Alexion, Alnylam, Argenx, Biogen, CSL Behring, Medscape, and Sanofi Genzyme; and has received research grants from Sanofi Genzyme and Akcea Therapeutics. Sami Khella reports honoraria from Akcea Therapeutics and Alnylam. Mathew S. Maurer reports grants from Pfizer and Alnylam; and personal fees from Pfizer, Eidos, GlaxoSmithKline, Prothena, Akcea Therapeutics, and Ionis.